Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Latest Content

Janssen unblinds Phase III TITAN study for prostate cancer

Janssen Pharmaceutical Companies of Johnson & Johnson has unblinded the Phase lll TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Related Treatments

Close
Close
Close

Go Top